Kim Klein1, Gertjan Kaspers1, Christine J Harrison1, H Berna Beverloo1, Ardine Reedijk1, Mathilda Bongers1, Jacqueline Cloos1, Andrea Pession1, Dirk Reinhardt1, Martin Zimmerman1, Ursula Creutzig1, Michael Dworzak1, Todd Alonzo1, Donna Johnston1, Betsy Hirsch1, Michal Zapotocky1, Barbara De Moerloose1, Alcira Fynn1, Vincent Lee1, Takashi Taga1, Akio Tawa1, Anne Auvrignon1, Bernward Zeller1, Erik Forestier1, Carmen Salgado1, Walentyna Balwierz1, Alexander Popa1, Jeffrey Rubnitz1, Susana Raimondi1, Brenda Gibson1. 1. Kim Klein, Gertjan Kaspers, Jacqueline Cloos, and Mathilda Bongers, Vrije Universiteit University Medical Center Amsterdam; Gertjan Kaspers and Ardine Reedijk, Dutch Childhood Oncology Group, The Hague; H. Berna Beverloo, Erasmus Medical Center, Rotterdam, the Netherlands; Christine J. Harrison, Newcastle University, Newcastle upon Tyne; Brenda Gibson, Royal Hospital for Sick Children, Glasgow, United Kingdom; Andrea Pession, Italian Association of Pediatric Hematology Oncology, Bologna, Italy; Dirk Reinhardt, Berlin-Frankfurt-Münster (BFM) -Germany, Essen; Martin Zimmerman and Ursula Creutzig, BFM-Germany, Hannover, Germany; Michael Dworzak, BFM-Austria, Vienna, Austria; Todd Alonzo, Donna Johnston, and Betsy Hirsch, Children's Oncology Group (COG) including Children's Cancer Group and Pediatric Oncology Group, Philadelphia (COG chair's office), PA; Michal Zapotocky, Czech Paediatric Hematology Working Group, Prague, Czech Republic; Barbara De Moerloose, European Organisation for Research and Treatment of Cancer-Children's Leukemia Group, Brussels, Belgium; Alcira Flynn, Grupo Argentino de Tratamiento de la Leucemia Aguda, Buenos Aires, Argentina; Vincent Lee, Hong Kong Paediatric Haematology and Oncology Study Group, Hong Kong, Special Administrative Region, People's Republic of China; Takashi Taga, Japanese Pediatric Leukemia/Lymphoma Study Group, Otsu; Akio Tawa, Japanese Pediatric Leukemia/Lymphoma Study Group, Osaka, Japan; Anne Auvrignon, French Leucémie Aiguë Myéloblastique Enfant Cooperative Group, Paris, France; Bernward Zeller, Nordic Society of Paediatric Haematology and Oncology, Oslo, Norway; Erik Forestier, Nordic Society of Paediatric Haematology and Oncology, Umeå, Sweden; Carmen Salgado, The National Program for Antineoplastic Drugs for Children, Santiago, Chile; Walentyna Balwierz, Polish Pediatric Leukemia Lymphoma Study Group, Krakow, Poland; Alexander Popa, Russian Acute Myeloid Leukemia Study Group, Moscow, Russia; and Jeffrey Rubnitz and
Abstract
PURPOSE: This retrospective cohort study aimed to determine the predictive relevance of clinical characteristics, additional cytogenetic aberrations, and cKIT and RAS mutations, as well as to evaluate whether specific treatment elements were associated with outcomes in pediatric t(8;21)-positive patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: Karyotypes of 916 pediatric patients with t(8;21)-AML were reviewed for the presence of additional cytogenetic aberrations, and 228 samples were screened for presence of cKIT and RAS mutations. Multivariable regression models were used to assess the relevance of anthracyclines, cytarabine, and etoposide during induction and overall treatment. End points were the probability of achieving complete remission, cumulative incidence of relapse (CIR), probability of event-free survival, and probability of overall survival. RESULTS: Of 838 patients included in final analyses, 92% achieved complete remission. The 5-year overall survival, event-free survival, and CIR were 74%, 58%, and 26%, respectively. cKIT mutations and RAS mutations were not significantly associated with outcome. Patients with deletions of chromosome arm 9q [del(9q); n = 104] had a lower probability of complete remission (P = .01). Gain of chromosome 4 (+4; n = 21) was associated with inferior CIR and survival (P < .01). Anthracycline doses greater than 150 mg/m(2) and etoposide doses greater than 500 mg/m(2) in the first induction course and high-dose cytarabine 3 g/m(2) during induction were associated with better outcomes on various end points. Cumulative doses of cytarabine greater than 30 g/m(2) and etoposide greater than 1,500 mg/m(2) were associated with lower CIR rates and better probability of event-free survival. CONCLUSION: Pediatric patients with t(8;21)-AML and additional del(9q) or additional +4 might not be considered at good risk. Patients with t(8;21)-AML likely benefit from protocols that have high doses of anthracyclines, etoposide, and cytarabine during induction, as well as from protocols comprising cumulative high doses of cytarabine and etoposide.
PURPOSE: This retrospective cohort study aimed to determine the predictive relevance of clinical characteristics, additional cytogenetic aberrations, and cKIT and RAS mutations, as well as to evaluate whether specific treatment elements were associated with outcomes in pediatric t(8;21)-positive patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: Karyotypes of 916 pediatric patients with t(8;21)-AML were reviewed for the presence of additional cytogenetic aberrations, and 228 samples were screened for presence of cKIT and RAS mutations. Multivariable regression models were used to assess the relevance of anthracyclines, cytarabine, and etoposide during induction and overall treatment. End points were the probability of achieving complete remission, cumulative incidence of relapse (CIR), probability of event-free survival, and probability of overall survival. RESULTS: Of 838 patients included in final analyses, 92% achieved complete remission. The 5-year overall survival, event-free survival, and CIR were 74%, 58%, and 26%, respectively. cKIT mutations and RAS mutations were not significantly associated with outcome. Patients with deletions of chromosome arm 9q [del(9q); n = 104] had a lower probability of complete remission (P = .01). Gain of chromosome 4 (+4; n = 21) was associated with inferior CIR and survival (P < .01). Anthracycline doses greater than 150 mg/m(2) and etoposide doses greater than 500 mg/m(2) in the first induction course and high-dose cytarabine 3 g/m(2) during induction were associated with better outcomes on various end points. Cumulative doses of cytarabine greater than 30 g/m(2) and etoposide greater than 1,500 mg/m(2) were associated with lower CIR rates and better probability of event-free survival. CONCLUSION: Pediatric patients with t(8;21)-AML and additional del(9q) or additional +4 might not be considered at good risk. Patients with t(8;21)-AML likely benefit from protocols that have high doses of anthracyclines, etoposide, and cytarabine during induction, as well as from protocols comprising cumulative high doses of cytarabine and etoposide.
Authors: Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: E Manara; V Bisio; R Masetti; V Beqiri; R Rondelli; G Menna; C Micalizzi; N Santoro; F Locatelli; G Basso; M Pigazzi Journal: Leukemia Date: 2013-11-14 Impact factor: 11.528
Authors: Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Christine von Neuhoff; Annette Sander; André Schrauder; Andrea Teigler-Schlegel; Jan Stary; Selim Corbacioglu; Dirk Reinhardt Journal: Blood Date: 2011-09-26 Impact factor: 22.113
Authors: J F Bishop; R M Lowenthal; D Joshua; J P Matthews; D Todd; R Cobcroft; M G Whiteside; H Kronenberg; D Ma; A Dodds Journal: Blood Date: 1990-01-01 Impact factor: 22.113
Authors: N Boissel; H Leroy; B Brethon; N Philippe; S de Botton; A Auvrignon; E Raffoux; T Leblanc; X Thomas; O Hermine; B Quesnel; A Baruchel; G Leverger; H Dombret; C Preudhomme Journal: Leukemia Date: 2006-06 Impact factor: 11.528
Authors: Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Gudrun Fleischhack; Norbert Graf; Thomas Klingebiel; Bernhard Kremens; Thomas Lehrnbecher; Christine von Neuhoff; Jörg Ritter; Annette Sander; André Schrauder; Arend von Stackelberg; Jan Starý; Dirk Reinhardt Journal: Blood Date: 2013-05-23 Impact factor: 22.113
Authors: Hyun Ae Jung; Chi Hoon Maeng; Silvia Park; Seok Jin Kim; Kihyun Kim; Jun Ho Jang; Chul Won Jung Journal: Anticancer Res Date: 2014-02 Impact factor: 2.480
Authors: J A Martinez-Climent; N J Lane; C M Rubin; E Morgan; H S Johnstone; R Mick; S B Murphy; J W Vardiman; R A Larson; M M Le Beau Journal: Leukemia Date: 1995-01 Impact factor: 11.528
Authors: Marlise R Luskin; Martin Carroll; David Lieberman; Jennifer J D Morrissette; Jianhua Zhao; Lisa Crisalli; David B Roth; Selina M Luger; David L Porter; Ran Reshef Journal: Biol Blood Marrow Transplant Date: 2016-07-28 Impact factor: 5.742
Authors: Soheil Meshinchi; Jessica A Pollard; Katherine Tarlock; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Rhonda Ries; Michael R Loken; Laura Pardo; Tiffany Hylkema; Jason Joaquin; Leela Sarukkai; Susana C Raimondi; Betsy Hirsch; Lillian Sung; Richard Aplenc; Irwin Bernstein; Alan S Gamis Journal: Clin Cancer Res Date: 2019-06-10 Impact factor: 12.531
Authors: Sanne Noort; Martin Zimmermann; Dirk Reinhardt; Wendy Cuccuini; Martina Pigazzi; Jenny Smith; Rhonda E Ries; Todd A Alonzo; Betsy Hirsch; Daisuke Tomizawa; Franco Locatelli; Tanja A Gruber; Susana Raimondi; Edwin Sonneveld; Daniel K Cheuk; Michael Dworzak; Jan Stary; Jonas Abrahamsson; Nira Arad-Cohen; Malgorzata Czogala; Barbara De Moerloose; Henrik Hasle; Soheil Meshinchi; Marry van den Heuvel-Eibrink; C Michel Zwaan Journal: Blood Date: 2018-08-27 Impact factor: 22.113
Authors: Thomas B Alexander; Lei Wang; Hiroto Inaba; Brandon M Triplett; Stanley Pounds; Raul C Ribeiro; Ching-Hon Pui; Jeffrey E Rubnitz Journal: Cancer Date: 2017-05-30 Impact factor: 6.860